Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Cullman Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$4,194,232

242 payments

Through program year 2025, Cullman Clinical Trials is reported as receiving $4,194,232 in research payments, across 242 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $778,677 151
2024 Research $1,205,694 39
2023 Research $1,345,042 16
2022 Research $721,038 30
2021 Research $138,190 3
2020 Research $5,590 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. Seqirus USA Inc $865,573 120 payments
  2. Sekisui Diagnostics LLC $751,295 5 payments
  3. AstraZeneca Pharmaceuticals LP $627,613 3 payments
  4. AstraZeneca UK Limited $556,140 3 payments
  5. Moderna TX, Inc. $326,627 10 payments
  6. OraSure Technologies Inc. $292,829 24 payments
  7. Regeneron Pharmaceuticals, Inc. $230,344 35 payments
  8. Pfizer Inc. $181,783 7 payments
  9. Visby Medical, Inc. $105,156 2 payments
  10. GlaxoSmithKline, LLC. $67,123 16 payments
Studies the money was for Research payments · program years 2020–2025
  1. Phase 1, Randomized, Open label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 and AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation versus Administration from Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants $606,413 2 payments
  2. Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/?or H5N6 Influenza Vaccine in Adults $577,775 11 payments
  3. A Phase I,Randomized,Safety and Pharmacokinetics Study of AZD3152 in Healthy Adults Little DIPPER $556,140 3 payments
  4. A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $326,627 10 payments
  5. A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity $230,344 35 payments
  6. A Multicenter Study to Evaluate the Performance of the OSOM Flu Home Test $213,975 1 payment
  7. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $213,233 100 payments
  8. Clinical Evaluation of the Sekisui Osom Covid-19 Antigen Home Test $207,350 1 payment
  9. A Multicenter Study Conducted to Evaluate the Performance of the InteliSwab COVID-19 Rapid Test $157,505 11 payments
  10. Performance Evaluation of the Lucira Covid19 Flu Test Kit Versus Fda Clearedauthorized Sarscov2 and Influenza AB Assays09acli001 $155,070 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record